Despite transforming the management of patients with haematological malignancies, autologous chimeric antigen receptor (CAR) T cell therapies have limitations. Now, the results of a phase I/II trial provide evidence of the feasibility, safety and efficacy of allogeneic CD19-directed CAR natural killer (NK) cells in patients with B cell malignancies.

中文翻译：

---

CAR NK 细胞的早期结果令人鼓舞

尽管改变了血液恶性肿瘤患者的治疗方法，但自体嵌合抗原受体 (CAR) T 细胞疗法仍存在局限性。现在，I/II 期试验的结果提供了同种异体 CD19 定向 CAR 自然杀伤 (NK) 细胞治疗 B 细胞恶性肿瘤患者的可行性、安全性和有效性的证据。